PharmaCyte Biotech Inc (PMCB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PharmaCyte Biotech Inc (PMCB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8077
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It develops cell-in-a-box cellulose-based live cell encapsulation technology. PharmaCyte’s treatment for pancreatic cancer consists of the combination of live cells encapsulated using Cell-in-a-Box technology together with low doses of the anticancer prodrug ifosfamide. It conducts research in the areas of live cell encapsulation technology, pancreatic cancer, diabetes, cannabinoids and cancer and breast cancer, among others. PharmaCyte is headquartered in Laguna Hills, California, the US.

PharmaCyte Biotech Inc (PMCB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
Partnerships 13
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 13
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 14
Licensing Agreements 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore for Cannabis Therapies 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore 16
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 17
Equity Offering 18
PharmaCyte Biotech to Raise up to USD25 Million in Public Offering of Shares 18
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 19
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 20
Nuvilex Completes First Tranche Of Private Placement Of Shares For US$2 Million 21
Nuvilex Competes Private Placement Of Securities For US$1.5 Million 22
Acquisition 23
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 23
Nuvilex Acquires Bio Blue Bird For US$1.5 Million 24
PharmaCyte Biotech Inc – Key Competitors 25
PharmaCyte Biotech Inc – Key Employees 26
PharmaCyte Biotech Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Oct 10, 2017: PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors 28
Jul 26, 2017: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 29
Jul 10, 2017: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 31
May 02, 2017: PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors 32
Apr 03, 2017: PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development 33
Legal and Regulatory 34
Nov 16, 2017: British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities 34
Government and Public Interest 36
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 36
Product News 37
Dec 05, 2017: PharmaCyte Biotech Announces Production of Master Cell Bank 37
Oct 17, 2017: PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer 38
04/18/2017: PharmaCyte Biotech Discusses Future of Cannabis Research Program, Competitors and More with Program’s Director 39
04/10/2017: PharmaCyte Biotech’s Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations 41
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 43
01/24/2017: PharmaCyte Going Head to Head with Eli Lillys Pancreatic Cancer Drug in New Clinical Trial 45
Jan 10, 2018: PharmaCyte Announces Completion of Master Cell Bank 47
Product Approvals 48
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 48
Jan 30, 2017: PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA 50
Jan 04, 2017: PharmaCyte Biotech Announces Pre-IND Meeting Date with FDA 51
Clinical Trials 52
Feb 21, 2017: PharmaCyte Biotech Discusses Patient Enrollment and TD2s Role in Upcoming Clinical Trial 52
Other Significant Developments 54
Feb 06, 2018: PharmaCyte Announces Completion of Preparatory Work and Commencement of Testing by Eurofins of Cells from Its Master Cell Bank 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 13
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 14
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore for Cannabis Therapies 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore 16
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 17
PharmaCyte Biotech to Raise up to USD25 Million in Public Offering of Shares 18
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 19
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 20
Nuvilex Completes First Tranche Of Private Placement Of Shares For US$2 Million 21
Nuvilex Competes Private Placement Of Securities For US$1.5 Million 22
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 23
Nuvilex Acquires Bio Blue Bird For US$1.5 Million 24
PharmaCyte Biotech Inc, Key Competitors 25
PharmaCyte Biotech Inc, Key Employees 26
PharmaCyte Biotech Inc, Subsidiaries 27

List of Figures
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[PharmaCyte Biotech Inc (PMCB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TAS Energy Inc:企業の戦略的SWOT分析
    TAS Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG; BAY 1905254, COM902 and TIGIT; and autoimmune diseases pipeline includes CGEN …
  • Gedeon Richter Plc:戦略・SWOT・企業財務分析
    Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report Summary Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Balaji Amines Ltd (BALAMINES)
    Balaji Amines Ltd (BALAMINES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Constant Contact, Inc.:企業の戦略・SWOT・財務分析
    Constant Contact, Inc. - Strategy, SWOT and Corporate Finance Report Summary Constant Contact, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Haoma Mining NL:企業の戦略・SWOT・財務情報
    Haoma Mining NL - Strategy, SWOT and Corporate Finance Report Summary Haoma Mining NL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Tervita Corp:企業の戦略・SWOT・財務分析
    Tervita Corp - Strategy, SWOT and Corporate Finance Report Summary Tervita Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • FMC Corp (FMC):企業の財務・戦略的SWOT分析
    FMC Corp (FMC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Applied Maths NV:医療機器:M&Aディール及び事業提携情報
    Summary Applied Maths NV (Applied Maths), a subsidiary of bioMerieux SA, is a bioinformatics company that designs, develops and markets bioscience software products. The company offers software products such as bionumerics, gelcompar II, bionumerics server and bionumerics calculation engine. Its bio …
  • Mediobanca Banca di Credito Finanziario S.p.A.:企業の戦略・SWOT・財務情報
    Mediobanca Banca di Credito Finanziario S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Mediobanca Banca di Credito Finanziario S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • First Gen Corp (FGEN):電力:M&Aディール及び事業提携情報
    Summary First Gen Corp (First Gen) a subsidiary of First Philippine Holding Corporation is a producer and distributor of electric power. It undertakes activities such as power generation, power distribution, infrastructure, manufacturing, and property development. The company together with its subsi …
  • Xeltis AG:企業の製品パイプライン分析2018
    Summary Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. The company’s polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process refe …
  • Public Power Corporation SA (PPC):電力:M&Aディール及び事業提携情報
    Summary Public Power Corporation SA (PPC) is a vertically integrated electric utility. It generates and supplies electricity. The company produces energy using lignite, gas, oil, hydro, wind and solar sources. PPC owns power generation projects across the country; holds interests in lignite mines in …
  • Cavitation Technologies Inc (CVAT):企業の財務・戦略的SWOT分析
    Summary Cavitation Technologies Inc (Cavitation) is an energy service company that develops processing technologies. The company processes fluidic mixtures, liquids, emulsions and suspended solids. Its technology uses hydrodynamic cavitation that comprise fluid’s vaporization and growth, pulsation, …
  • UCB Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary UCB Inc (UCB), a subsidiary of UCB SA, is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, meta …
  • GW Pharmaceuticals Plc (GWPH):企業の財務・戦略的SWOT分析
    GW Pharmaceuticals Plc (GWPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Altin Yunus Cesme Turistik Tesisler A.S.:企業の戦略・SWOT・財務情報
    Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report Summary Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Big River Gold Ltd (CAS):企業の財務・戦略的SWOT分析
    Summary Big River Gold Ltd (Big River Gold) is formerly known as Crusader resources Ltd is a mineral exploration company. The company explores for gold, iron ore and tin deposits. Its projects portfolio includes Borborema Gold project, Posse Iron Ore project, Tarantula Tungsten project, Juruena Gold …
  • Aegion Corp (AEGN):企業の財務・戦略的SWOT分析
    Aegion Corp (AEGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Ribomic Inc (4591):製薬・医療:M&Aディール及び事業提携情報
    Summary Ribomic Inc (Ribomic), a subsidiary of Otsuka Pharmaceutical Co Ltd, is a biopharmaceutical venture company. The company develops molecular targeted pharmaceutical drugs using RNA aptamers. Its technology includes RiboART system a platform technology to treat therapeutic aptamers. Ribomic’s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆